PET-directed therapy in Hodgkin lymphoma: Ready for prime time?

References

• Hodgkin T. On some morbid appearances of the absorbent glands and spleen. 1832
   Google Scholar
• Reed DM. On the pathological changes in hodgkin’s disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 1902;10:133-96
   Google Scholar
• Pusey WA. Cases of sarcoma and of hodgkin’s disease treated by exposures to x-rays—a preliminary report. J Am Med Assoc 1902;38(3):166-9
   Google Scholar
• Hoppe RT. Evolution of the techniques of radiation therapy in the management of lymphoma. Int J Clin Oncol 2013;18(3):359-63
   PubMed Web of Science ®Google Scholar
• Cowan DH. Vera peters and the curability of hodgkin disease. Curr Oncol 2008;15(5):206-10
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Kaplan HS. The evolution and summary results of the stanford randomized clinical trials of the management of hodgkin’s disease: 1962-1984. Int J Radiat Oncol Biol Phys 1985;11(1):5:22
   Web of Science ®Google Scholar
• Hoster HA, Dratman MB. Hodgkin’s disease, 1832-1947. Cancer Res 1948;8(1):1; passim
   PubMed Web of Science ®Google Scholar
• Krumbhaar EB. Role of the blood and the bone marrow in certain forms of gas poisoning: I. peripheral blood changes and their significance. J Am Med Assoc 1919;72(1):39-41
   Google Scholar
• Diehl V. Hodgkin’s disease--from pathology specimen to cure. N Engl J Med 2007;357(19):1968-71
   PubMed Web of Science ®Google Scholar
• Goodman LS, Wintrobe MM. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 1946;132:126-32
   PubMed Web of Science ®Google Scholar
• Devita VTJr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced hodgkin’s disease. Ann Intern Med 1970;73(6):881-95
   PubMed Web of Science ®Google Scholar
• Ziegler JL, Fass L, Bluming AZ, et al. Chemotherapy oif childhood hodgkin’s disease in uganda. Lancet 1972;2(7779):679-82
   PubMed Web of Science ®Google Scholar
• Olweny CL, Katongole-Mbidde E, Kiire C, et al. Childhood hodgkin’s disease in uganda: A ten year experience. Cancer 1978;42(2):787-92
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36(1):252-9
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, stanford V, and adjuvant radiotherapy for bulky or advanced-stage hodgkin’s disease: A preliminary report. J Clin Oncol 1995;13(5):1080-8
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Hasenclever D, et al. BEACOPP: A new regimen for advanced hodgkin’s disease. german hodgkin’s lymphoma study group. Ann Oncol 1998;9(Suppl 5):S67-71
   PubMedGoogle Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on hodgkin’s disease staging classification. Cancer Res 1971;31(11):1860-1
   PubMed Web of Science ®Google Scholar
• Beckmann EC. CT scanning the early days. Br J Radiol 2006;79(937):5-8
   PubMed Web of Science ®Google Scholar
• Castellino RA, Hoppe RT, Blank N, et al. Computed tomography, lymphography, and staging laparotomy: Correlations in initial staging of hodgkin disease. Am J Roentgenol 1984;143(1):37-41
   PubMed Web of Science ®Google Scholar
• Reznek RH, Richards MA. The radiology of lymphoma. Baillieres Clin Haematol 1987;1(1):77-107
   PubMedGoogle Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7(11):1630-6
   PubMed Web of Science ®Google Scholar
• Blackledge G, Best JJK, Crowther D, Isherwood I. Computed tomography (CT) in the staging of patients with hodgkin’s disease: A report on 136 patients. Clin Radiol 1980;31(2):143-7
   PubMed Web of Science ®Google Scholar
• Schaefer NG, Hany TF, Taverna C, et al. Non-hodgkin lymphoma and hodgkin disease: Coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Radiology 2004;232(3):823-9
   PubMed Web of Science ®Google Scholar
• Bonte FJ. Nuclear medicine pioneer citation, 1976: David E. kuhl, M.D. J Nucl Med 1976;17(6):518-19
   PubMedGoogle Scholar
• Devizzi L, Maffioli L, Bonfante V, et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal hodgkin’s disease. Ann Oncol 1997;8 Suppl 1:53-56
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002;94(4):879-88
   PubMed Web of Science ®Google Scholar
• Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104(5):1066-74
   PubMed Web of Science ®Google Scholar
• Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: A systematic review. Blood 2008;111(2):504-16
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. Position emission tomography with or without computed tomography in the primary staging of hodgkin’s lymphoma. Haematologica 2006;91(4):482-9
   PubMed Web of Science ®Google Scholar
• Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage hodgkin’s lymphoma. Br J Cancer 2004;90(3):620-5
   PubMed Web of Science ®Google Scholar
• Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29(14):1844-54
   PubMed Web of Science ®Google Scholar
• Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(5 Suppl):1S-93S
   PubMed Web of Science ®Google Scholar
• Adams HJ, Kwee TC, de Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed hodgkin lymphoma: Is bone marrow biopsy still necessary? Ann Oncol 2014;25(5):921-7
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw 2015;13(5):554-86
   PubMed Web of Science ®Google Scholar
• Stevens WB, van Krieken JH, Mus RD, et al. Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed hodgkin lymphoma. Ann Oncol 2012;23(10):2676-81
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leukemia & lymphoma 2009;50:8:1257-60
   PubMed Web of Science ®Google Scholar
• Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54(5):683-90
   PubMed Web of Science ®Google Scholar
• de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in hodgkin’s lymphoma. Ann Oncol 2001;12(1):29-37
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal hodgkin disease. Blood 2001;98(10):2930-4
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115(2):272-8
   PubMed Web of Science ®Google Scholar
• Molnar Z, Simon Z, Borbenyi Z, et al. Prognostic value of FDG-PET in hodgkin lymphoma for posttreatment evaluation. long term follow-up results. Neoplasma 2010;57(4):349-54
   PubMed Web of Science ®Google Scholar
• Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage hodgkin lymphoma. Blood 2008;112(10):3989-94
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579-86
   PubMed Web of Science ®Google Scholar
• Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for hodgkin’s disease: Too many clinic visits and routine tests? A review of hospital records. BMJ 1997;314(7077):343-6
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with hodgkin’s disease. Ann Oncol 2003;14(1):123-30
   PubMed Web of Science ®Google Scholar
• Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of hodgkin lymphoma patients in first remission: A clinical and economic analysis. Cancer 2010;116(16):3835-42
   PubMed Web of Science ®Google Scholar
• Pingali SR, Jewell SW, Havlat L, et al. Limited utility of routine surveillance imaging for classical hodgkin lymphoma patients in first complete remission. Cancer 2014;120(14):2122-9
   PubMed Web of Science ®Google Scholar
• Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic significance of mid- and post-ABVD PET imaging in hodgkin’s lymphoma: The importance of involved-field radiotherapy. Ann Oncol 2009;20(11):1848-53
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Evens AM. FDG-PET imaging for hodgkin lymphoma: Current use and future applications. Clin Adv Hematol Oncol 2014;12(1):20-35
   PubMedGoogle Scholar
• Armitage JO. Early-stage hodgkin’s lymphoma. N Engl J Med 2010;363(7):653-62
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with hodgkin’s lymphoma. J Clin Oncol 2005;23(30):7614-20
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89(4):854-62
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for hodgkin’s disease. J Clin Oncol 2003;21(18):3431-9
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for hodgkin’s lymphoma: A collaborative british cohort study. J Clin Oncol 2011;29(31):4096-104
   PubMed Web of Science ®Google Scholar
• Koh ES, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for hodgkin’s lymphoma: Reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007;2:13
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for hodgkin lymphoma. Blood 2007;109(5):1878-86
   PubMed Web of Science ®Google Scholar
• Hoppe RT. Hodgkin’s disease: Complications of therapy and excess mortality. Ann Oncol 1997;8(Suppl 1):115-18
   PubMed Web of Science ®Google Scholar
• Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 2004;22(1):62-8
   PubMed Web of Science ®Google Scholar
• Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky hodgkin disease. Blood 2004;104(12):3483-9
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage hodgkin’s lymphoma. N Engl J Med 2012;366(5):399-408
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage hodgkin’s lymphoma. N Engl J Med 2010;363(7):640-52
   PubMed Web of Science ®Google Scholar
• Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014;32(12):1188-94
   PubMed Web of Science ®Google Scholar
• Meyer RM. Limited-stage hodgkin lymphoma: Managing uncertainty. J Clin Oncol 2014;32(12):1180-2
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage hodgkin’s lymphoma. N Engl J Med 2015;372(17):1598-607
   PubMed Web of Science ®Google Scholar
• Longo DL, Armitage JO. Controversies in the treatment of early-stage hodgkin’s lymphoma. N Engl J Med 2015;372(17):1667-9
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced hodgkin’s disease. N Engl J Med 2003;348(24):2386-95
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27(27):4548-54
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365(3):203-12
   PubMed Web of Science ®Google Scholar
• Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage hodgkin’s lymphoma: A systematic review and network meta-analysis. Lancet Oncol 2013;14(10):943-52
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with hodgkin lymphoma: A report from the german hodgkin study group. Blood 2014;123(11):1658-64
   PubMed Web of Science ®Google Scholar
• Wongso D, Fuchs M, Plutschow A, et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: An analysis of the german hodgkin study group. J Clin Oncol 2013;31(22):2819-24
   PubMed Web of Science ®Google Scholar
• Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152(5):551-60
   PubMed Web of Science ®Google Scholar
• Press O, Li H, Schoder H. Response adapted therapy of stage III-IV hodgkin lymphoma based on interim FDG-PET imaging: Early results of US intergroup S0816. Haematologica 2013;98(Suppl 2):36
   Google Scholar
• Gallamini A, Rossi A, Patti C, et al. Early treatment intensification in advanced-stage high-risk hodgkin lymphoma (hl) patients, with a positive fdg-pet scan after two abvd courses–second interim analysis of the gitil/fil hd0607 clinical trial haematologica. 2013;98(Suppl 2):3
   Google Scholar
• Johnson P, Federico M, Fossa A, et al. Response rates and toxicity of response-adapted therapy in advanced hodgkin lymphoma: Initial results from the international rathl study. Haematologica 2013;98:2
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Rigacci L, Stefoni V, et al. Early interim 18F-FDG PET in hodgkin’s lymphoma: Evaluation on 304 patients. Eur J Nucl Med Mol Imaging 2012;39(1):4-12
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced hodgkin’s disease. international prognostic factors project on advanced hodgkin’s disease. N Engl J Med 1998;339(21):1506-14
   PubMed Web of Science ®Google Scholar
• Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk hodgkin’s lymphoma. Ann Oncol 2010;21(1):126-32
   PubMed Web of Science ®Google Scholar
• Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk hodgkin lymphoma with no impairment of outcome. Blood 2007;109(3):905-9
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 2014;32(27):3048-58
   PubMed Web of Science ®Google Scholar
• Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01132807
   Google Scholar
• Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01118026
   Google Scholar
• HD16 for early stage hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00736320
   Google Scholar
• HD17 for intermediate stage hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01356680
   Google Scholar
• Chemotherapy based on PET scan in treating patients with stage I or stage II hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01390584
   Google Scholar
• Pilot study of abbreviated chemotherapy based on positron emission tomography (PET) scan in Hodgkin’s Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00901303
   Google Scholar
• HD18 for advanced stages in hodgkins Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00515554
   Google Scholar
• Study of a treatment driven by early PET response to a treatment not monitored by early PET in patients with AA stage 3-4 or 2B HL (AHL 2011). Available from: https://clinicaltrials.gov/ct2/show/NCT01358747
   Google Scholar
• Tailored therapy for hodgkin Lymphoma using early interim therapy PET for therapy decision. Available from: https://clinicaltrials.gov/ct2/show/NCT00392314
   Google Scholar